Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Endometrial Neoplasms 2Solid Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lung Neoplasms 1Advanced Solid Tumor 1

Interventions

Rituximab 295Cyclophosphamide 240Peripheral Blood Stem Cell Transplantation 114fludarabine phosphate 110Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 79Vincristine 78Prednisone 77Mycophenolic Acid 66Doxorubicin 61Cyclosporine 59Whole-Body Irradiation 58Bendamustine Hydrochloride 58Melphalan 57Tacrolimus 53Busulfan 51fludarabine 50Cytarabine 48obinutuzumab 46Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 32ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Follicular × Appointments and Schedules × Clear all
NCT02631044 2024-06-27

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Juno Therapeutics, a Subsidiary of Celgene

Phase 1 Completed
387 enrolled 2 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡